Editorial Videos

Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib combination to address unmet needs in second-line treatment for endometrial carcinoma patients.

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, explains how E7386 and lenvatinib work together to target advanced endometrial carcinoma through dual mechanisms of action and WNT pathway modulation.

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how long-term LEAP-002 data provides critical reassurance around Lenvima’s durability and safety in treating unresectable hepatocellular carcinoma.

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of unresectable hepatocellular carcinoma.

Marcel Botha discusses whether AI can truly be used to replace laid off human workers at FDA.

Marcel Botha discusses ways the agency can ensure it gets the most accurate results possible from AI.

Marcel Botha discusses what the technology is most effective at in the FDA approval process.

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, outlines how the company is working to ease care transitions, support community oncologists, and reduce overwhelm in cancer treatment delivery.

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, shares how the company is supporting cancer care teams through timely education, community-based trials, and tools to manage complex treatment transitions.

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of collaboration across the healthcare community to develop inclusive and effective AI solutions that enhance decision-making and patient outcomes in oncology.

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine discusses key takeaways from the Oncology Care Index and how they are shaping the company’s approach to clinical research, community partnerships, and continuity of care.

Pedro Valencia, VP, asset strategy, leadership, oncology, AbbVie, outlines how the company is accelerating development across lung, gastrointestinal, and ovarian cancers following ASCO 2025, with a focus on advancing antibody drug conjugates and expanding late-stage studies.

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine explains how insights from the Oncology Care Index are helping address oncologists’ challenges with keeping up amid a surge in cancer treatment breakthroughs.

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company partners with patient advocacy groups to identify unmet needs and prioritize patient-centered benefits in the development of innovative cancer therapies.

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, discusses how early data from ABBV-706 shows up to 50% response rates in rare neuroendocrine tumors, offering a potential advance over traditional chemotherapy.

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company is advancing Temab-A across multiple tumor types targeting c-Met, with the goal of establishing it as a pipeline-in-a-molecule.

Pedro Valencia, VP, asset strategy leadership, oncology, outlines how unmet need, treatment stagnation, and pipeline innovation shape the company’s approach to solid tumor oncology following key data presented at ASCO 2025.

Ron Lanton, Partner, Lanton Law, discusses the constitutional and statutory challenges facing the President’s use of executive orders to implement international drug pricing models such as the Most Favored Nation, highlighting the ongoing debate over separation of powers and congressional authority.

Ron Lanton, Partner, Lanton Law, outlines how the MFN executive order may face significant legal challenges from the pharmaceutical industry, citing concerns over due process, intellectual property, and regulatory overreach.

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, discusses the company's nationwide push to reduce cardiovascular risk through free LDL-C testing, public-private partnerships, and implementation science initiatives—all aimed at cutting CV events in half by 2030.

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why seamless communication and treatment continuity across primary care, cardiology, and rehabilitation are critical to improving outcomes and preventing care gaps for cardiovascular patients.

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, discusses how new findings highlight the need for simplified decision-making in lipid management and a stronger focus on achieving LDL-C targets to help prevent heart attacks and strokes.

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why many high-risk Americans aged 50+ remain undertreated for cardiovascular disease, citing insurance gaps, risk misperceptions, and complex guidelines.

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, discusses new real-world data showing that most high-risk cardiovascular patients in the US are not starting or intensifying lipid-lowering therapy—and few are achieving guideline-recommended LDL-C targets.

Armando Castro, partner, emerging companies, venture capital, Lowenstein Sandler, explains how regulatory, patent, and reimbursement challenges are slowing venture investment in GLP-1 and psychedelic addiction therapies.

Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement challenges, shifting distribution models, and expanding the drugs’ potential into new therapeutic areas.

Will Pih, co-founder, Two Labs, explains how ongoing regulatory uncertainty is slowing clinical trial activity and hiring across the industry, prompting greater reliance on specialty pharmacy services and outsourced support.

Blake Powers, CEO, medigi, explains how digital tools, AI, and automation are streamlining access to biosimilars and cell and gene therapies, signaling a shift toward more tech-enabled, patient-centric care.